Search

Displaying results 4081 - 4090 of 10000 in total
  1. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who … [L49266] It was approved alongside [exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based gene therapies for the treatment of SCD in patients

  2. Drug

    Saprisartan

    go.drugbank.com/drugs/DB01347
    Experimental

    The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan. … Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure.

    Categories: Agents Acting on the Renin-Angiotensin System, Angiotensin II receptor antagonists
  3. Drug

    Polaprezinc

    go.drugbank.com/drugs/DB09221
    Investigational

    Polaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308]. … A study in 2013 showed that CO-administration of polaprezinc may be effective against small intestine mucosal injury associated with long-term aspirin therapy [A7840].

  4. Drug

    Olesoxime

    go.drugbank.com/drugs/DB05185
    Investigational

    For example, it has demonstrated the ability to prevent neurodegeneration, enhance nerve function and accelerate neuroregeneration following nerve trauma.[A3282,A253233] … Olesoxime is a cholesterol-like small molecule that has demonstrated a remarkable neuroprotective profile in a battery of both in vitro and in vivo preclinical models.

    Synonyms: (EZ)-N-(CHOLEST-4-EN-3-YLIDENE)HYDROXYLAMINE, cholest-4-en-3-one, oxime
  5. Drug

    Lomustine

    go.drugbank.com/drugs/DB01206
    ApprovedInvestigational

    An alkylating agent of value against both hematologic malignancies and solid tumors.

    Synonyms: N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea
  6. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

  7. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    For LY2140023, the active substance, LY404039, is thought to work by reducing the presynaptic release of another neurotransmitter, glutamate, in brain regions where mGlu2/3 receptors are expressed. … Further studies are planned or are ongoing to learn more about the safety and effectiveness, including determining an optimal therapeutic dose for LY2140023.

  8. Drug

    TM30339

    go.drugbank.com/drugs/DB05085
    Experimental

    TM30339 thus imitates a natural mechanism, a satiety signal from the gastrointestinal system involved in the regulation of food intake in humans. TM30339 is developed for the treatment of obesity. … TM30339 works through the same receptor as the natural satiety hormone, Pancreatic Polypeptide (PP), but TM30339 has improved properties compared with PP.

  9. Drug

    HY10275

    go.drugbank.com/drugs/DB05079
    Experimental

    HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep. … This dual-acting receptor activity and the lack of affinity for undesired off- target receptors are thought to account for the compounds excellent efficacy and tolerability profile.

  10. Drug

    Litifilimab

    go.drugbank.com/drugs/DB18864
    Investigational

    SCLE) And/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations and Refractory And/or Intolerant to Antimalarial Therapy). … Litifilimab is under investigation in clinical trial NCT05531565 (A Study to Assess the Efficacy and Safety of BIIB059 (Litifilimab) in Participants With Active Subacute Cutaneous Lupus Erythematosus (